All Articles

A professional steering committee for Great Lakes Health Hospital System identified the need to coordinate and integrate an organized oncology service line and attain Commission on Cancer accreditation.

The first cases of COVID-19 in the United States were reported in early January 2020 and began rapidly increasing in March 2020.

Oncology nurse navigators and administrative staff reported spending more than half their daily shifts in some way managing incoming calls and the backlog of voicemails.

One recent study revealed that lung cancer was the most common cancer among those uninsured.

This year, there are no accepted abstracts within this research category.

Acalabrutinib is a next-generation, highly selective, covalent Bruton tyrosine kinase inhibitor approved for patients with CLL, including those with R/R CLL.

Two large phase 3 studies (COMBI-d [NCT01584648] and COMBI-v [NCT01597908]) evaluated the efficacy and safety of oral dabrafenib 150 mg twice daily plus trametinib 2 mg once daily (D+T) as first-line therapy in patients (pts) with BRAF V600E- or V600K-mutant unresectable or metastatic cutaneous melanoma.

Lenvatinib plus pembrolizumab demonstrated promising antitumor activity in endometrial carcinoma (EC) in a phase 1b/2 clinical trial (Study 111/KEYNOTE-146).

Luteinizing hormone-releasing hormone (LHRH) agonists are the most frequently used androgen deprivation therapy (ADT) for prostate cancer (PCa).

Clinical pathways have increasingly been incorporated into cancer care, aiming to encourage high-quality, evidence-based care while minimizing costs; however, clinical pathways infrequently incorporate patient and family perspectives, limiting patient-centeredness and value for shared decision-making.